ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

  • October 1, 2013

Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable production process under current Good Manufacturing Practices (cGMPs) to produce toxicology and Phase I clinical supply at its state-of-the-art facility located in Rockville, MD.

The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Dr. Wendy Picking at the Department of Microbiology and Molecular Genetics, Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes.

Dr. Thomas VanCott, President and CEO of ABL, stated, “We are very pleased to have been chosen by PATH to be the contract manufacturer for this important vaccine candidate. Our expertise in the areas of cGMP manufacturing, assay development, and project management combine to provide a unique and comprehensive service for vaccine development from early-stage discovery to clinical trials.”

About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, process and assay development, preclinical in vivo studies, in vitro laboratory services including immunomonitoring, and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com. Follow ABL on LinkedIn.